Nektar Therapeutics
![Nektar Therapeutics](https://api.admiralmarkets.com/trade_icons/bright-128/NKTR.png)
Closed
1.14 1.79
Overview
Share price change
24h
Min
1.14
Max
1.17
Income | -46M |
---|---|
Sales | -259K 24M |
EPS | -0.22 |
Profit margin | -189.848 |
Employees | 137 |
EBITDA | -32M |
Recommendations | Buy |
---|---|
12 Months Forecast | +78.57 upside |
Next Earnings | 5 Nov 2024 |
---|
Market Cap | -20M 230M |
---|---|
Previous open | -0.65 |
Previous close | 1.14 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Nektar Therapeutics Chart
Related News
Peer Comparison
Price change
Nektar Therapeutics Forecast
Price Target
By TipRanks
78.57% upside
12 Months Forecast
Average 2 USD 78.57%
High 2 USD
Low 2 USD
Based on 2 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.